Edgar Filing: Calithera Biosciences, Inc. - Form 4

Calithera Bios Form 4 August 24, 20											
FORM Check this	4 UNITED	 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 20(b) of the Investment Company Act of 1940 								PPROVAL 3235-0287	
if no longe subject to Section 16 Form 4 or Form 5 obligation may contin <i>See</i> Instruct 1(b).	Filed pur Section 17(Expires: January 31 200 Estimated average burden hours per response 0.	
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> Hecht Curtis			2. Issuer Name and Ticker or Trading Symbol Calithera Biosciences, Inc. [CALA]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	(First) (1 HERA BIOSCIE YSTER POINT		3. Date of (Month/D 08/20/20	-	ansaction			Director X Officer (give below)	10%	Owner er (specify	
	(Street)	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
SOUTH SAN FRANCISCO									Aore than One Re		
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	Securi	ties Acc	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Executio any		3. Transactic Code (Instr. 8) Code V	on(A) or Di (D) (Instr. 3,	spose	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	08/20/2015			М	2,000	A	\$ 2.64	8,625 <u>(1)</u>	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)				8. H Dei Sec (In:
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 2.64	08/20/2015		М	2,000	(2)	04/21/2024	Common Stock	2,000	

Edgar Filing: Calithera Biosciences, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships						
1 8-	Director	10% Owner	Officer	Other				
Hecht Curtis C/O CALITHERA BIOSCIENCES, INC. 343 OYSTER POINT BLVD. #200 SOUTH SAN FRANCISCO, CA 94080			VP, BUS. & CORP. DEVELOPMENT					

Signatures

/s/ Curtis C. 08/24/2015 Hecht Date

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v). *
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Includes 2,500 shares acquired under the Company's 2014 Employee Stock Purchase Plan on May 15, 2015. (1)
- 1/48 of the Option vests in equal monthly installments one month from 04/21/2014. The option shall be subject to accelerated vesting as (2) set forth in the optionee's employment agreement with the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.